Office :

Sedayu Square D-7, Cengkareng

Jakarta Barat, DKI Jakarta 11730
Phone +21 22552090

Factory :
Blok A1 No.5 Tegal Alur, Kalideres
Jakarta Barat, DKI Jakarta 11820
Phone +21 55952077
COMPANY PROFILE 1
 PT TAISHAN ALKES
INDONESIA

PRODUSEN RAPIDTEST ANTIBODY

& RAPIDTEST SWAB ANTIGEN
MERK CLUNGENE
DI INDONESIA

SARS-CoV-2 (Covid-19)
 PT TAISHAN ALKES INDONESIA

PT. Taishan Alkes Indonesia adalah perusahaan nasional yang menjadi pioner produsen
Rapid Test SWAB Antigen dan Rapid Test Antibodi untuk mengetahui seseorang terinfeksi
positif atau negative terhadap virus Covid-19, yang dalam hal ini bekerja sama dan
didukung sepenuhnya oleh salah satu perusahaan international terkemuka yakni
Hangzhou Clongene Biotech Co.,Ltd dalam memproduksi Rapid Test Kit dan Rapid Test
SWAB untuk memenuhi kebutuhan dalam negeri dan ekspor.
Sebagai Autorized Distributor merk Clungene di Indonesia, PT. Taishan Alkes Indonesia
mendapat komitmen dukungan technical dan transfer technology secara penuh dari
Hangzhou Clongene Biotech Co.Ltd , termasuk pengembangan produk-produk lainnya di
masa akan dating.

3
 VISI DAN MISI

Visi kami adalah “Kami ingin dikenal sebagai perusahaan yang menyediakan produk
dan jasa yang dapat dipercaya, penuh inovasi, bertanggung jawab dan fleksibel.”

Misi kami adalah menjadi manufaktur resmi dalam menyediakan alat rapid test yang
disesuaikan dengan kebutuhan dan harapan masyarakat Indonesia.

4
 OUR TEAM
EIKO SIHOMBING SH.
Mr Eiko Sihombing, Expert staff of former General Army and Minister of administrative and Bureaucratic Reform TB. Silalahi.
Highly Motivated hard working person with admistration management skill. Previos Professional experience in managing a few difference energy and
mining company. Director of Dairi Clean Energy, Development director of Fukukawa, Director of Sumber Bumi Marau and PT Taishan Alkes
Indonesia.
Involves in Developing Renewable energy biomass power plant, Mini Hydro Seluma Energi, and Mining industry.
Obtained Bachelor Degree of Law from Jakarta University Tama Jagakarsa.

President Director

CAHYADI BURHAN S.KOM

Mr Cahyadi Burhan, Director of Greentech Global Engineering and President Commissioner of Taishan Alkes Indonesia.
Obtained Bachelor Degree of Computer Science from Jakarta University Bina Nusantara.
Dynamic and motivated professional hard working person with professional sales and marketing, administration management skill, relentless
problem-solver, professional with a proven record of generating and building relationships, managing projects from concept to completion, designing
educational strategies, and coaching individuals to success. Skilled in building cross-functional teams, demonstrating exceptional communication
skills, and making critical decisions during challenges. Adaptable and transformational leader with an ability to work independently, creating effective
presentations, and developing opportunities that further establish company goals.

President Commissioner
Dr. Ir SUMANGGAR MILTON PAKPAHAN, MM,CERG
Dr. Milton has extensive experience in the fields of public policy, energy, management, having served in various important positions in oil & gas companies, coal mining,
contracting and business advisors as well as a lecturer in practicing postgraduate programs at the PLN Institute of Technology. Professional experience as CEOs from KKBrothers
Groups, Board of Commissioners of PT Dirgantara 2016-2020, Board of commissioners of PT PLN (Persero) 2014-2015, Directorate of Processing PT Pertamina 1990-1996
Members of the 2009-2014 MPR / DPR RI and the chairman of Commission VII in charge of Energy, Environment and Technology Research, so that they really understand the
government's policy in implementing the national energy application, which has participated as a member of the special committee drafting laws in the energy sector, such as
The Oil and Gas Bill, the Mineral and Coal Bill, Government Regulations on National Energy Policy and others.
Dr. Milton has received very intensive education and training in the fields of risk management, information technology, power generation, new and renewable energy, oil & gas,
mining, construction and research and technology during his career in government and private organizations. Dr. Milton has a physical engineering degree, graduated from the
Bandung Institute of Technology, received a master's degree in management from the Indonesian Business & Informatics Institute, and received a Doctor of Public Policy in the
field of Energy and National Electricity Policy from Brawijaya University, Faculty of Administrative Sciences, Malang
Commissioner 2
LEGALITAS
AGREEMENT OF DISTRIBUTOR

8
LEGALITAS
LETTER OF AGREEMENT

9
LEGALITAS
PRODUCT QUALITY EQUIVALENT dan ISO 13485

10
LEGALITAS
SERTIFIKAT PRODUKSI dan DISTRIBUSI ALAT KESEHATAN KEMENKES

11
 COVI
D-19An genRapi
d
Tes
tCas
see

HangzhouCl
ongeneBi
otechnol
ogyCo.
,Lt
d PTTai
shanAl
kesI
ndonesi
a
Add:No.1YichuangRoad,YuhangSub-
YuhangDi
str
ict
,31
1
di
121Hangzhou,Chi
st
na
ri
ct, SedayuSquar
Jakart
aBar
eD-7,Cengkar
atDKIJakart
a1
eng,
1730
KEMENKESRIAKL20303120677

.T
PT ai
shanAl
kesI
ndones
ia
IsanI ndonesiancompanyt hathasbec omeapi oneerinmanuf act
uri
ngCov i
d-19I gG/I gM
ABOUT RapidTestandCov ic-
19An genRapidT es
t. PT.T ais
hanAl k
esI ndonesi
ai sinc ooper aon Ki
tCont
ent
s Pr
oduct
sFeat
ures
US wi t
hHangz huoClongeneBiot
ech,Co.
L t
dChinat opr ovi
det ec
hnicalsupportandt echnology
transf
erint heproduconpr oces
soft heRapidTes tdevi
ces,includi
ngfuturedev elopment
forotherproducts.I
naddiont oproduconc ooperaon,PT .Tai
shanAlkesIndonesiaal soact
s CEMaer
ked

asanaut hori
zeddi s
tri
but
orforHangzhuoClongeneBi ot h,Co.
ec Lt
dpr oduct
sinIndones a.
i
Easyt
ocol
lectsampl
es

Noequi
pmentr
equi
red

I
nst
antr
esul
tat15mi
nut
es

Resul
tsar
ecl
ear
lyvi
sibl
e

Sui
tabl
eforl
arge-
scal
erapi
dscr
eeni
ng

Pr
inci
ple
T
h eCOVID-
19Ang enRapi
dTesti
sal
ater
alfl owimmun oas
sayint
endedf
orthequali
ty
det
eco nSARS
-CoV-2nuc
leoc
apsi
dang e
n si
nn as
ophar
yngeals
waba ndor
opharyng
eal
s
wa bfr
omindi
vidual
swhoaresus
pec
tedof COVI
D-19bythei
rheal
tca
repr
ovide.
r

S
ampl
ePa
d Conj
uga
tePa
d NCmembr
ane Abs
orbentPa
d

COVI
D-19&SARS-
CoV-
2 S
ARS
-CoV-
2NPmAbc
onj
uga
tedwi
thc
olormi
cropa
rcl
es S
ARS
-CoV-
2NPmAb Cont
rol
li
ne

TheCOVID- 19An genTesti

salat
eralflowimmunoassaybasedonthepri
ncipleofthedouble-
an bodysandwicht
echnique.I
fthespeci
men
COVID-19anac uter espir
atoryintecousc aus
edbynov elcoronavi
rus(SARS-CoV-
12)
, cont
ainsSAR-CoV-2an gen,acol
oredtes
tl i
ne(T)wouldbevisi
bl
eintheresultwindow.AbsenceoftheTl i
nesuggestsanegaver esul
t.
andpeopl ear
eg ener allysuscep ble.Basedont hecurr
entepidemi ol
ogi
cali
nvesg aon, Thecontrolli
ne(C)isusedforprocedur
alcont
rol,andshoul
dal
waysappearifthetestpr
ocedur
eisperfor
medpropely.
theincubaonper iodi s1to14da ys,mostly3to7da y.Nov
s elcoronavi
rusi
ncludesf
our
typi
calstruct
uralpr ot eins :Spi
k eprotein,Env el
opeprotei
n,Membr aneproteinand
Nucleocapsi
dprotein.

Speci
mens

SPr
otei
n T
hede
tec
tspe
cime
nsi
ncl
udena
sopha
ryng
eal
swa
bandor
opha
ryng
eal
s b.
wa

Na
sophar
yngea
lswa
b Or
ophar
yng
eal
swa
b

N-
Prot
ein I
nadequat
es pec
imencol
lecon,
impr
opers
pec
imenhandl
i
ngand/
ortr
anspor
tma
yyie
ldfa
lser
esul
ts;
the
ref
ore
,
t
rai
ni
nginspe c
imencoll
econishi
ghl
yrec
ommendedduetotheimpor
tanc
eofspec
imenquali
tytoobt
ain
a
ccurat
etestres
ult
s.
Nucl
eocapsi
d(N)pr
otei
nisthemostabundantpr
otei
nwithhig
hlycons
erv
edin
SARS-
CoV-2.Nprot
eini
susedast
hecorera
wma t
eri
alofr
api
ddiag
noscreage
nt
f
orimmunologyint
hema r
ket.
 COVI
D-19An genRapi
d
Tes
tCas
see

HangzhouCl
ongeneBi
otechnol
ogyCo.
,Lt
d PTTai
shanAl
kesI
ndonesi
a
Add:No.1YichuangRoad,YuhangSub-
YuhangDi
str
ict
,31
1
di
121Hangzhou,Chi
st
na
ri
ct, SedayuSquar
Jakart
aBar
eD-7,Cengkar
atDKIJakart
a1
eng,
1730
KEMENKESRIAKL20303027943

.T
PT ai
shanAl
kesI
ndones
ia
IsanI ndonesiancompanyt hathasbec omeapi oneerinmanuf act
uri
ngCov i
d-19I gG/I gM
ABOUT RapidTestandCov ic-
19An genRapidT es
t. PT.T ais
hanAl k
esI ndonesi
ai sinc ooper aon Ki
tCont
ent
s Pr
oduct
sFeat
ures
US wi t
hHangz huoClongeneBiot
ech,Co.
L t
dChinat opr ovi
det ec
hnicalsupportandt echnology
transf
erint heproduconpr oces
soft heRapidTes tdevi
ces,includi
ngfuturedev elopment
forotherproducts.I
naddiont oproduconc ooperaon,PT .Tai
shanAlkesIndonesiaal soact
s CEMaer
ked

asanaut hori
zeddi s
tri
but
orforHangzhuoClongeneBi ot h,Co.
ec Lt
dpr oduct
sinIndones a.
i
Easyt
ocol
lectsampl
es

Noequi
pmentr
equi
red

I
nst
antr
esul
tat15mi
nut
es

Resul
tsar
ecl
ear
lyvi
sibl
e

Sui
tabl
eforl
arge-
scal
erapi
dscr
eeni
ng

Pr
inci
ple
T
h eCOVID-
19Ang enRapi
dTesti
sal
ater
alfl owimmun oas
sayint
endedf
orthequali
ty
det
eco nSARS
-CoV-2nuc
leoc
apsi
dang e
n si
nn as
ophar
yngeals
waba ndor
opharyng
eal
s
wa bfr
omindi
vidual
swhoaresus
pec
tedof COVI
D-19bythei
rheal
tca
repr
ovide.
r

S
ampl
ePa
d Conj
uga
tePa
d NCmembr
ane Abs
orbentPa
d

COVI
D-19&SARS-
CoV-
2 S
ARS
-CoV-
2NPmAbc
onj
uga
tedwi
thc
olormi
cropa
rcl
es S
ARS
-CoV-
2NPmAb Cont
rol
li
ne

TheCOVID- 19An genTesti

salat
eralflowimmunoassaybasedonthepri
ncipleofthedouble-
an bodysandwicht
echnique.I
fthespeci
men
COVID-19anac uter espir
atoryintecousc aus
edbynov elcoronavi
rus(SARS-CoV-
12)
, cont
ainsSAR-CoV-2an gen,acol
oredtes
tl i
ne(T)wouldbevisi
bl
eintheresultwindow.AbsenceoftheTl i
nesuggestsanegaver esul
t.
andpeopl ear
eg ener allysuscep ble.Basedont hecurr
entepidemi ol
ogi
cali
nvesg aon, Thecontrolli
ne(C)isusedforprocedur
alcont
rol,andshoul
dal
waysappearifthetestpr
ocedur
eisperfor
medpropely.
theincubaonper iodi s1to14da ys,mostly3to7da y.Nov
s elcoronavi
rusi
ncludesf
our
typi
calstruct
uralpr ot eins :Spi
k eprotein,Env el
opeprotei
n,Membr aneproteinand
Nucleocapsi
dprotein.

Speci
mens

SPr
otei
n T
hede
tec
tspe
cime
nsi
ncl
udena
sopha
ryng
eal
swa
bandor
opha
ryng
eal
s b.
wa

Na
sophar
yngea
lswa
b Or
ophar
yng
eal
swa
b

N-
Prot
ein I
nadequat
es pec
imencol
lecon,
impr
opers
pec
imenhandl
i
ngand/
ortr
anspor
tma
yyie
ldfa
lser
esul
ts;
the
ref
ore
,
t
rai
ni
nginspe c
imencoll
econishi
ghl
yrec
ommendedduetotheimpor
tanc
eofspec
imenquali
tytoobt
ain
a
ccurat
etestres
ult
s.
Nucl
eocapsi
d(N)pr
otei
nisthemostabundantpr
otei
nwithhig
hlycons
erv
edin
SARS-
CoV-2.Nprot
eini
susedast
hecorera
wma t
eri
alofr
api
ddiag
noscreage
nt
f
orimmunologyint
hema r
ket.
TARGET PRODUKSI
Q4 2020-Q1 2021
04
MILESTONE
Pengembangan Pabrik
Q1 2021
3.000.000 Pcs Selesai Diproduksi
Peningkatan Kapasitas Produksi

03
MILESTONE
Produksi Batch 2 Selesai
Q1 2021
02
MILESTONE 2.000.000 Pcs Selesai Diproduksi
Produksi Batch 1 Selesai
01
MILESTONE Q4 2020
Mulai Produksi 1.000.000 Pcs Selesai Diproduksi
Q4 2020
250.000 Pcs per minggu

W1 W2 W3 W4 W1 W2 W3 W4 W1 W2 W3 W4 W1 W2 W3 W4

Nov 2020 Des 2020 Jan 2021 Feb 2021

11
PRODUCTION LINE
Capacity : 200,000-250.000 Pcs per Day

12
PRODUCTION LINE
Capacity : 200,000-250.000 Pcs per Day

13
PRODUCTION LINE
Capacity : 200,000-250.000 Pcs per Day

14
PRODUK
RAPID TEST KIT – SWAB
ANTIGEN UKURAN BOX
Isi = 25 Set Kit
L = 26,5 cm
T = 6,5 cm
D = 12,0 cm

UKURAN KARTON
Isi = 50 Doz
L = 63,5 cm
T = 55,0 cm
D = 34,0 cm

16
PRODUK
RAPID TEST KIT
ANTIBODY UKURAN BOX
Isi = 25 Set Kit
L = 21,0 cm
T = 6,5 cm
D = 12,0 cm

UKURAN KARTON
Isi = 50 Doz
L = 63,5 cm
T = 45,0 cm
D = 34,0 cm

17
FAMILY SCREENING PACK
ISI 12 SET, Lebih Praktis dan Efesien

UKURAN BOX
Isi = 12 Set Kit
L = 19,0 cm
T = 6,7 cm
D = 12,4 cm

UKURAN PACK
.

L = 11,9 cm
T = 1,4 cm
D = 6,2 cm

18
PRODUK
RAPID TEST KIT – ANTIBODY RAPID TEST KIT – SWAB ANTIGEN

19
THANK
YOU
cs.taishanindonesia@gmail.com